Physician profile
Mark Anthony Gonzalez
NPI 1134866221
$1,021.22
in general payments reported to CMS, 2019-2025
22 companies · $577 in 2025
The $577 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $46.85 · 2023: $261 · 2024: $137 · 2025: $577.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $974.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $974.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $152.21 | 2024-2025 | Airsupra, Farxiga |
| Otsuka America Pharmaceutical, INC. | $138.33 | 2023-2025 | Rexulti, Nuedexta |
| Insmed, INC. | $124.98 | 2025 | Brinsupri |
| E.R. Squibb & Sons, L.L.C. | $99.81 | 2022-2023 | Camzyos |
| Novo Nordisk INC | $84.84 | 2023-2025 | Ozempic, Rybelsus |
| Melinta Therapeutics, LLC | $51.52 | 2025 | Rezzayo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.41 | 2024-2025 | Jardiance |
| Amgen INC. | $40.60 | 2023-2025 | Repatha, Otezla, Repatha |
| Organogenesis INC. | $37.81 | 2025 | Affinity |
| Abbvie INC. | $35.47 | 2023-2024 | |
| Optinose US, INC. | $23.14 | 2025 | |
| Pfizer INC. | $21.05 | 2025 | |
| Exact Sciences Corporation | $19.06 | 2025 | The Cologuard Plus Collection Kit |
| Nevro Corp. | $18.70 | 2023 | Senza |
| Axonics, INC. | $18.07 | 2023 | Axonics |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $17.20 | 2023 | Quviviq |
| Novartis Pharmaceuticals Corporation | $16.63 | 2022 | |
| Lilly USA, LLC | $16.33 | 2025 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $16.12 | 2024 | Arexvy, Shingrix |
| Organon LLC | $14.21 | 2023 | Nexplanon |
| Takeda Pharmaceuticals U.S.A., INC. | $13.54 | 2023 | Trintellix |
| Astellas Pharma US INC | $13.19 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Gonzalez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.